P1042: SAFETY AND TOLERABILITY RESULTS FROM THE PHASE 3B FREEDOM TRIAL OF FEDRATINIB (FEDR), AN ORAL, SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH MYELOFIBROSIS (MF) PREVIOUSLY TREATED WITH RUXOLITINIB (RUX)

MLA

V. Gupta, et al. “P1042: Safety and Tolerability Results from the Phase 3B Freedom Trial of Fedratinib (Fedr), an Oral, Selective Jak2 Inhibitor, in Patients with Myelofibrosis (Mf) Previously Treated with Ruxolitinib (Rux).” HemaSphere, vol. 6, June 2022, pp. 932–33. EBSCOhost, https://doi.org/10.1097/01.hs9.0000847036.30498.e9.

APA

V. Gupta, A. Yacoub, S. Verstovsek, R. A. Mesa, C. N. Harrison, G. Barosi, J.-J. Kiladjian, H. J. Deeg, S. Fazal, L. Foltz, R. J. Mattison, C. B. Miller, V. Parameswaran, C. Hernandez, J. Zhang, & M. Talpaz. (2022). P1042: Safety and Tolerability Results from the Phase 3B Freedom Trial of Fedratinib (Fedr), an Oral, Selective Jak2 Inhibitor, in Patients with Myelofibrosis (Mf) Previously Treated with Ruxolitinib (Rux). HemaSphere, 6, 932–933. https://doi.org/10.1097/01.hs9.0000847036.30498.e9

Chicago

V. Gupta, A. Yacoub, S. Verstovsek, R. A. Mesa, C. N. Harrison, G. Barosi, J.-J. Kiladjian, et al. 2022. “P1042: Safety and Tolerability Results from the Phase 3B Freedom Trial of Fedratinib (Fedr), an Oral, Selective Jak2 Inhibitor, in Patients with Myelofibrosis (Mf) Previously Treated with Ruxolitinib (Rux).” HemaSphere 6 (June): 932–33. doi:10.1097/01.hs9.0000847036.30498.e9.